Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19.
In a paper published in the journal Nanoscale, researchers from the University’s Centre of Excellence for Long-acting Therapeutics (CELT) demonstrate the nanoparticle formulation of niclosamide, a highly insoluble drug compound, as a scalable long-acting injectable antiviral candidate.
The team started repurposing and reformulating identified drug compounds with the potential for COVID-19 therapy candidates within weeks of the first lockdown. Niclosamide is just one of the drug compounds identified and has been shown to be highly effective against SARS-CoV-2 in a number of laboratory studies.
Using their expertise in the fields of materials chemistry, long-acting drug delivery and pharmacology, CELT scientists used nanoprecipitation to form redispersible solid drug nanoparticle formulations of niclosamide that can be stored as solids, reconstituted with water and utilised as long acting injectables. Their research has demonstrated sustained circulating drug concentrations may be maintained for the duration of early infection after a single injection.
Professor Steve Rannard said: “Repurposing drug compounds is much more than using existing medicines for a new disease. The existing active drug compound needs to be shown to be active at a significant level, then reformulated to address new challenges. The conventional route of administration may also not be relevant and modifying the way the patient receives the drug compound is highly critical to efficacy. Niclosamide is an ideal candidate to be taken forward as a potential long acting injectable therapeutic to treat Covid-19.
“This is still in early-stage development but the CELT team are currently working with a contract manufacturing organisation to take this forward towards scale up and clinical manufacture. This work is progressing well and if successful, human trials would be next. We envisage a future `Test-and-Treat’ scenario where infected people are treated at the point of diagnosis with the full course of therapy in one injection.”
Professor Andrew Owen said: “Repurposing of medicines for SARS-CoV-2 has yielded mixed results, with some clear successes for immunomodulatory drugs such as dexamethasone, and work underway to repurpose drugs like favipiravir and molnupiravir that were designed for other viruses.
“The ultimate utility of our long-acting injectable can only be determined in adequately powered and well controlled randomised clinical trials but unlike other drugs that have been explored for repurposing niclosamide target concentrations may be achievable in humans. The formulation has shown great promise in preclinical studies at a time when it is increasingly evident that drugs are urgently required to compliment the vaccines.
“A global pandemic requires a global solution, and it is critical that interventions are available to everyone and not to the privileged few. Accordingly, we are currently working to remove obstacles to availability in low- and middle-income countries to ensure equitable access if clinical success is ultimately demonstrated.”
Image Credit: Getty
Researchers from Hong Kong Baptist University (HKBU), in collaboration with Cornell University, have developed a novel targeted therapy for triple-negative breast cancer (TNBC) that uses a specially-designed nano-carrier to deliver the Chinese medicine compound [...]
By early 2020, concern was mounting about a new, deadly coronavirus first detected in Wuhan, China. The World Health Organization had declared the coronavirus outbreak a global health emergency just days before. There had been [...]
As a COVID-19 and medical device researcher, I understand the importance of face masks to prevent the spread of the coronavirus. So I am intrigued that some mask manufacturers have begun adding graphene coatings [...]
Swansea University scientists have uncovered potentially dangerous chemical pollutants that are released from disposable face masks when submerged in water. The research reveals high levels of pollutants, including lead, antimony, and copper, within the [...]
Bowel cancer survival rates could be improved if chemotherapy drugs were delivered via tiny nanoparticles to the diseased organs rather than oral treatment. That's the finding from Indian and Australian scientists who have undertaken [...]
Pfizer CEO Albert Bourla says his company’s experimental COVID-19 treatment, a pill that can be taken at the first sign of the illness, could be available before the end of the year. Speaking on CNBC, Bourla said clinical [...]
At the University of Chicago, scientists have developed an absolutely innovative, promising treatment for COVID-19 in the form of nanoparticles with the ability to trap SARS-CoV-2 viruses inside the body and use the body’s [...]
Australian researchers have identified neutralizing nanobodies that block the SARS-CoV-2 virus from entering cells in preclinical models. The discovery paves the way for further investigations into nanobody-based treatments for COVID-19. Published in PNAS, the research [...]
Someday, scientists believe, tiny DNA-based robots and other nanodevices will deliver medicine inside our bodies, detect the presence of deadly pathogens, and help manufacture increasingly smaller electronics. Researchers took a big step toward that [...]
Experts have discovered what they believe is the world’s most mutated COVID strain – and there’s one detail in particular that has scientists worried. Scientists have detected what is believed to be the world’s [...]
SARS-CoV-2, the virus that causes COVID-19, likely does not directly infect the brain but can still inflict significant neurological damage, according to a new study from neuropathologists, neurologists, and neuroradiologists at Columbia University Vagelos [...]
ANSTO has contributed to a comprehensive investigation of a promising type of nanoparticle that could potentially be used for intractable brain cancers in a combined therapy. The study, which was led by Dr. Moeava [...]
The immune response needed to protect people against reinfection with the coronavirus will be explored in a new human challenge trial, researchers have revealed. Human challenge trials involve deliberately exposing healthy people to a [...]
Researchers from Duke University are developing a flu shot with the new technology that was used for two coronavirus vaccines. Both the Pfizer-BioNTech and the Moderna shots use part of the virus's genetic code [...]
Researchers from the University of Liverpool have shown the potential of repurposing an existing and cheap drug into a long-acting injectable therapy that could be used to treat Covid-19. In a paper published in the journal Nanoscale, [...]